AJH-2947
/ J Mackem
- LARVOL DELTA
Home
Next
Prev
1 to 2
Of
2
Go to page
1
February 21, 2026
TRPV1 Receptor Modulators: Emerging Therapies for Neuropathic, Osteoarthritic, and Perioperative Pain.
(PubMed, CNS Drugs)
- "Promising pharmaceutical agonists for pain include low- and high-dose capsaicin formulations, resiniferatoxin, CNTX-4975, and vocacapsaicin. Potentially applicable antagonist drugs include NEO6860, Mavatrep, ACD-440, AJH-2947, DWP05195, and XEN-DO501. As our understanding of TRPV1 channels has continued to increase since the initial discovery, we are at last beginning to see some positive clinical developments for TRPV1 drugs in the realm of neuropathic, post-operative, musculoskeletal, and cancer pain."
Journal • Musculoskeletal Diseases • Musculoskeletal Pain • Oncology • Osteoarthritis • Pain
October 17, 2024
A Study to Investigate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics After Oral Administration of AJH-2947 in Healthy Korean and/or Caucasian Adult Male Subjects
(clinicaltrials.gov)
- P1 | N=68 | Enrolling by invitation | Sponsor: JMackem Co., Ltd | Recruiting ➔ Enrolling by invitation | Trial completion date: Apr 2025 ➔ Sep 2025
Enrollment status • Trial completion date • Diabetic Neuropathy • Neuralgia • Pain
1 to 2
Of
2
Go to page
1